Atavistik Bio

About Atavistik Bio

Atavistik Bio is a biopharmaceutical company that discovers and develops precision allosteric small molecule therapeutics to address unmet needs in oncology and rare diseases. Founded in 2021 by Jared Rutter, PhD, and Ralph DeBerardinis, MD, PhD, the Cambridge, Massachusetts-based firm leverages a platform technology that originated from its founders' research. Rutter is a Professor of Biochemistry at the University of Utah and a Howard Hughes Medical Institute Investigator, known for his work on metabolite-protein interactions. DeBerardinis is a professor at the University of Texas Southwestern Medical Center and a practicing medical geneticist focused on human metabolism. The leadership team includes CEO Bryan E. Stuart, who has over 20 years of experience in the biopharma industry, and President and CSO Marion Dorsch, PhD, a veteran of drug discovery who has contributed to six FDA-approved precision medicines.

The company's core technology is its proprietary Atavistik Metabolite-Protein Screening (AMPS) platform, which is integrated with an AI-enabled discovery engine. This platform uses metabolites—the body's natural regulators of protein function—as bait to identify previously hidden, or cryptic, allosteric sites on proteins. Allosteric sites are regulatory pockets on a protein distinct from the active site, and targeting them allows for the development of highly selective drugs. This approach enables the company to drug targets previously considered intractable, aiming for therapeutics with superior efficacy and better tolerability profiles. Atavistik's business model centers on advancing its internal pipeline while also forming strategic partnerships to apply its platform to other therapeutic areas. The company generates revenue through collaboration agreements, which may include milestone payments and royalties. In January 2025, Atavistik announced a research collaboration with Pfizer to identify allosteric binders for two undisclosed oncology targets.

Atavistik has raised significant capital to fund its operations, securing a $60 million Series A in August 2021 and a Series B round totaling $160 million by March 2026, with investors including The Column Group, Nextech Invest, Lux Capital, RA Capital Management, and Regeneron Ventures. The company's internal pipeline is focused on precision oncology and rare diseases. Its lead program is ATV-1601, an oral, allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT), a severe bleeding disorder with no currently approved therapies. A clinical trial for HHT is anticipated to begin in the first half of 2026. Another key program is a JAK2 V617F mutant-selective inhibitor for myeloproliferative neoplasms (MPNs), a group of chronic blood cancers. This selective targeting aims to provide disease-modifying efficacy while avoiding the side effects associated with broader JAK inhibition.